Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
M.D. Anderson Cancer Center
ImmunityBio, Inc.
Mayo Clinic
University of Pittsburgh
7 Hills Pharma, LLC
Incyte Corporation
Bristol-Myers Squibb
Sarcoma Oncology Research Center, LLC
Molecular Templates, Inc.
Bayer
Tempest Therapeutics
Fate Therapeutics
Jules Bordet Institute
Incyte Corporation